Enantiomeric drug development: issues, considerations, and regulatory requirements.

Enantiomeric drug development: issues, considerations, and regulatory requirements.

Item
http://www.wikidata.org/entity/Q34464369
Evolution of stimulants to treat ADHD: transdermal methylphenidateUse of online-dual-column extraction in conjunction with chiral liquid chromatography tandem mass spectrometry for determination of terbutaline enantiomers in human plasma.Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.Enantiomeric separation of meptazinol and its three intermediate enantiomers by capillary electrophoresis: quantitative analysis of meptazinol in pharmaceutical formulations.Chromatographic and electrophoretic strategies for the chiral separation and quantification of d- and l-threo methylphenidate in biological matrices.Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist.Enantiomeric separation of racemic 4-aryl-1,4-dihydropyridines and 4-aryl-1,2,3,4-tetrahydropyrimidines on a chiral tetraproline stationary phase.Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus?Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors.Bioanalysis of chiral compounds during drug development using a tiered approach.
P2860

Enantiomeric drug development: issues, considerations, and regulatory requirements.

Item
http://www.wikidata.org/entity/Q34464369
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@ast
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@en
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@nl
type
label
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@ast
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@en
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@nl
prefLabel
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@ast
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@en
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P356
P1433
P1476
Enantiomeric drug development: issues, considerations, and regulatory requirements.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698